Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.In an interview with Healio, ...

driven by continued strong prescription trends in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis. Hence, Regeneron has ...

Regeneron stock has trended bearishly since ... These indications include asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, among others.

The global atopic dermatitis treatment market is on the cusp of remarkable expansion, with projections indicating a surge in ...

Regeneron recently announced that the primary ... Solid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and ...